Interest in use of the psoralen compounds as a possible prophylactic against cancer of the skin followed several years of their empirical use in the treatment of vitiligo. These early efforts to confirm impressions of clinical usefulness were disappointing and resulted in diversion of the principal research efforts toward elucidation of basic mechanisms of photodynamic response of the skin, with the empirical investigations assuming a position of lesser but still complementary importance.
By 1956 a working hypothesis had evolved of possible practical significance. The considerations leading to this hypothesis were described in a preliminary report of these trials (1) : one, patients using psoralen for vitiligo reported protection against sunburn (2); two, controlled experiments showed primary effects of psoralen, whether administered orally or topically, to be potentiation of the skth in its erythema and pigmentation responses to ultraviolet irradiation (3) ; three, the apparent protective effect of psoralen against sunburn could be explained as a secondary result of increased activity of the skin in raising its normal defenses by thickening of the stratum corneum and, finally, other layers, which then became effective against subsequent ultraviolet irradiation; four, experiments with ultraviolet induced skin cancers in albino mice (4) were interpreted as showing that a high dose of psoralen had augmented skin responses to ultraviolet irradiation beyond physiologically tolerable levels, causing trauma and subsequently triggering malignant growth. On the other hand, a low dose had been sufficient to stimulate an increase in the normal protective responses of the skin against the carcinogenic action of the cal tolerance. It was not possible to specify hosv this secondary protective effect might be operating, since the mechanism was not known for either the psoralen activity or the carcinogenesis. Since the mice were albino it was assumed that at least the pigment factor could be ruled out as having a protective effect; five, epidemiologic surveys based on cancer registries brought out that skin cancers are more prevalent on exposed areas of the head) neck and hands among light skinned people in high, dry and sunny climates than elsewhere (5) .
While psoralen was no longer believed to afford any primary shielding in the sense of a simple sunscreen or ultraviolet absorber, it was reasoned that at low dose levels it would, without causing trauma, increase physiological pigmentation and cornification of the epidermis sufficient to filter out a significantly increased amount of ultraviolet energy. A small daily dose of oral psoralen for an outdoor worker might build up in the skin a natural protective covering. It was hypothesized that reduction of cumulative ultraviolet to a point below the carcinoma triggering level could be attained by this approach.
Low toxicity and good human tolerance of orally administered psoralen in the form of methoxsalen in low doses had been demonstrated (6) . While the mechanism of action was not understood, it was reasoned that if cancer protection could possibly eventuate, some risk was acceptable. Accordingly, a clinical trial was set up.
METHOD AND MAIEEJAL5
A community (El Paso, Texas) was located in which a functioning cancer registry, which included dermatologists' offices as well as clinics, laboratories and hospitals, showed high incidence of cancer of the skin of the face and hands, with some 1,500 living cases on the register. It also happened to be a high, dry, sunny locale inhabited by 2 contrasting dermatologic groups, one lightly and the other rather darkly pigmented. A small group of dermatologists who see a large proportion of the skin affections of the locale agreed to conduct a trial study under our direction. We supplied the drugs, special study forms, and a clerk to work in their offices interviewing the patients, recording the data, dispensing the drugs, monitoring the follow-up, and generally assuming the innumerable small extra burdens imposed by a study. It cannot be overemphasized that the success of a clinical trial depends on provision of effective staff work of this sort.
All patients who already had 2 or more skin cancers or keratoses on head, neck or hands and were willing to enter the study were admitted. Once admitted they were given a study number and study interview which included inventory with photographs, of all lesions present, and skin color readings on the reflectance meter. They were given a 3 months' supply of the medication and instructions for its use. At 3 months intervals they returned for examination by the physician, follow-up interview and photographs, and refill of their drug supply.
Control of the drug effect was obtained by use of 2 different psoralen compounds, A and B, which, if our hypothesis was even approximately correct, would produce distinctly different prophylactic effects. The 2 "drugs" were allocated to the patients individually and blindly according to a prearranged drawing of random numbers. They were supplied by the manufacturer in identical appearing bottles and capsules bearing oniy the general "psoralen" name and the name and number of the patient. Only after our analysis of the results had been completed and our conclusions drawn did we decode and relate effects to the specific drugs. The patients were all told that theywere occurring during each trial period (3 months). 50 per cent versus 25 per cent having new lesions, It was expected that about half of the patients between the 2 treatment groups. The sequential would produce new lesions in a given period, plan gave a 95 per cent chance of detecting an The statistical control unit for the trial moniadverse effect and a 90 per cent chance of detecting tored the records sequentially so that the trial a prophylactic effect if such existed, and permitted could be stopped as soon as a statistically signifius to stop the trial as soon as such an effect became cant decision became possible. Patients on the evident. 2 contrast drugs were paired randomly and ana-For this part of the trial, the immediate effects lyzed sequentially following the Bross (7) plan part, we anticipated following about 500 patients for detection of a moderate difference. This plan for 2 years. To initiate studies of latent effects guaranteed a good chance of detecting a true we provided for 100 of the patients to be selected at entry into the study as long-termers who would stay in a continued study for 5 years or more. By comparing rates of new lesions in their first, second, third and up to twentieth 3 months period we hoped to get information on latent and cumulative effects of the drugs.
The median induction time for the appearance of new lesions in all the patients in the registry with more than 1 lesion on the exposed areas of the head, neck and hands was 18 months. It was therefore expected that 50 per cent of the patients Table I .
The conclusion with respect to prophylactic effect of the psoralen treatment is negative. The 2 drugs had essentially equal effects. Decoding revealed that the drugs were: A: 20 mg methox-Reason Nausea Nausea and other reasons. Tables II through V. Table II shows the distribution of patients by age, sex, occupation, drug allocation, and number of initial lesions (lesions observed before entry into study). Table III gives the record of incidence of new lesions, by successive periods of treatment. Outdoor occupations included 72 percent of the patients, but 85 percent of the reports of new lesions, lending support to the initial hypothesis of relationship between solar exposure and skin cancer induction. The number of females is so small, and is concentrated so heavily in occupations not subject to solar exposure, that the sex breakdown is not continued in subsequent tables.
In Table IV incidence rates of new lesions per patient examined and per patient with any new lesions are given. These rates appear to be essentially constant through the 24 months of the trial and equal for the drug treatments.
Finally, an analysis of the dropouts is given in prophylactic against skin cancer was tested in a double-blind controlled trial. Subjects were 141 middle aged men, and 32 women, primarily in outdoor occupations, who had already had at least 1 histologically verified skin cancer.
2. Methoxsalen was administered at the rate of 20 mg daily by mouth, taken in the morning. Patients were seen every 3 months for inventory of new lesions.
3. Side effects were minimal. Dropouts were equally frequent in methoxsalen and inert control series.
4. Effective dose level and patient adherence were confirmed by observation of the expected primary effect, increased sunburn, and later, tanning, in the methoxsalen patients. Increased sunburn and tanning were the only significant differences obtained in the 2 series. 5. By the time 24 controlled pairs of patients had been followed 1 year and the results analyzed sequentially, the decision was reached that there was no difference between the methoxsalen patients and their inert drug treated controls in the incidence of new lesions. At this time 12 patients had been treated for 2 full years on methoxsalen and 13 on control. 6 . It is concluded that methoxsalen in humanly tolerable tanning doses has no immediate effect on incidence of new lesions of skin cancer.
Whether larger doses or treatment over a longer period than 2 years might be effective cannot be determined from this trial.
